Study of YTS104 cell therapy for hard-to-treat myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 1 study tests an injected cell therapy (YTS104) for people with multiple myeloma that has come back or did not respond after several prior treatments. The goal is to see whether the treatment is safe and may help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18–75 years old, and have relapsed or refractory multiple myeloma after at least three prior treatment lines (including a proteasome inhibitor and an immunotherapy drug).
- Have clear signs the disease is getting worse during treatment or within 12 months after your last anti-myeloma therapy.
- Have measurable myeloma in blood or urine tests at screening (for example, specific M-protein or free light chain results).
- Be well enough for treatment: organ function is acceptable, ECOG performance status is 0–1, and expected survival is at least 12 weeks.
- Be able to use effective birth control if you could become pregnant (or if your partner could).
- Meet key safety checks: no allergy to the cell product, no major recent heart/stroke/serious rhythm problems, and no recent blood clots or major lung infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called YKST02 for people with multiple myeloma that has come back or hasn't responded to other treatments. The goal is to see if it can help when other therapies have stopped working.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins on myeloma cells: GPRC5D and CD19. It is for people whose myeloma has come back or stopped responding to at least 3 prior treatments. The goal is to see if this treatment is safe and helps control the disease.
This trial tests a new drug, YKST02, for adults with multiple myeloma that has returned or not responded after at least two previous treatments. It may be an option if you have already tried certain standard therapies.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
This trial tests a new type of immune cell therapy (called CAR T-cells) designed to treat advanced multiple myeloma that has not responded well to standard treatments. The study focuses on safety and how well your body tolerates this personalized cell therapy.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.